WHOLE-BODY DIFFUSION-WEIGHTED MRI VERSUS FDG PET/CT IN MULTIPLE MYELOMA: A PRISMA-BASED SYSTEMATIC REVIEW HIGHLIGHTING DISEASE STAGING AND CLINICAL VALUE IN GLOBAL HEMATOLOGY AND LOW-RESOURCE SETTINGS

EHA Library, KALYSTA BORGES, 4208481

EFFICACY AND SAFETY OF IXAZOMIB PLUS REDUCED-DOSE LENALIDOMIDE VERSUS IXAZOMIB MONOTHERAPY AS MAINTENANCE IN HIGH‑RISK NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF A PROSPECTIVE STUDY

EHA Library, Xuzhao Zhang, 4208482

PROGNOSTIC VALUE OF MINIMAL RESIDUAL DISEASE STATUS FOR SURVIVAL OUTCOMES IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A META-ANALYSIS

EHA Library, Hira Mian, 4208483

OVERALL SURVIVAL OF ANTI-BCMA THERAPIES: INDIRECT COMPARISON OF BELANTAMAB MAFODOTIN/BORTEZOMIB/DEXAMETHASONE (BVD) VS TECLISTAMAB/DARATUMUMAB (TEC-DARA) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Joshua Richter, 4208484

PROGRESSION OF DISEASE WITHIN 24 MONTHS (POD24) IS AN INDEPENDENT PROGNOSTIC FACTOR FOR SURVIVAL IN NEWLY DIAGNOSED PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA TREATED WITH DRC

EHA Library, Maria Gavriatopoulou, 4208485

DUFFY NULL GENOTYPE MODIFIES TREATMENT OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): EVIDENCE FROM THE COMMPASS STUDY

EHA Library, Chaitanya Acharya, 4208486

HYPERDIPLOID MULTIPLE MYELOMA: GENETIC HETEROGENEITY

EHA Library, Anikó Ujfalusi, 4208487

GAPS IN ACCESS TO CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY POST LEUKAPHERESIS: WAITING TIME AND TREATMENT PATTERNS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: REAL‑WORLD EVIDENCE FROM US CLAIMS

EHA Library, John Hartman, 4208488

DEVELOPMENT AND PRELIMINARY CONTENT VALIDATION OF THE PROSIM‑Q: A PATIENT‑REPORTED OCULAR SYMPTOM AND IMPACT QUESTIONNAIRE FOR ONCOLOGY TRIALS

EHA Library, Farrah Pompilus, 4208489

SUSTAINED MRD WITH OR WITHOUT ASCT IN THE ERA OF NEW REGIMENS FOR MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND NETWORK ANALYSIS

EHA Library, Marco Rossi, 4208490

BCMA-DIRECTED CAR-T CELL THERAPY IN MULTIPLE MYELOMA PATIENTS REQUIRING HEMODIALYSIS (HD): A MULTICENTER REAL-WORLD ANALYSIS

EHA Library, James Di Palma-Grisi, 4208491

REAL-WORLD TREATMENT PATTERNS AND SURVIVAL OUTCOMES IN PATIENTS WITH MULTIPLE MYELOMA AFTER 1–2 PRIOR LINES OF THERAPY FROM THE HONEUR FEDERATED DATA NETWORK

EHA Library, Markus Rückert, 4208492

DUAL-RISK ADJUSTED THERAPY FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA BASED ON DYNAMIC FRAILTY ASSESSMENT AND R-ISS: A PROSPECTIVE CLINICAL TRIAL

EHA Library, Hua Xue, 4208493

EFFICACY OF VENETOCLAX-BASED THERAPY IN T(11;14)–POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS.

EHA Library, Vasu Malhotra, 4208494

REAL‑WORLD IMPACT OF ANTI‑CD38 MONOCLONAL ANTIBODY THERAPY AND HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PRIMARY PLASMA CELL LEUKEMIA: A SINGLE‑CENTER STUDY

EHA Library, Vincent Luong, 4208495

REAL-WORLD SAFETY OF ELRANATAMAB IN PATIENTS WITH RENAL IMPAIRMENT: FINDINGS FROM THE SUMMIT STUDY

EHA Library, Satoshi Yoshihara, 4208496

REAL-WORLD SAFETY OF ELRANATAMAB IN LOW-WEIGHT PATIENTS: FINDINGS FROM THE SUMMIT STUDY

EHA Library, Satoshi Yoshihara, 4208497

EFFICACY AND SAFETY OF REDUCED-DOSE DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE (DVD-LITE) IN NEWLY DIAGNOSED MGRS PATIENTS

EHA Library, Huan Xie, 4208498

CO-OCCURRENCE, TIMING, AND SURVIVAL IN COMPOSITE HEMATOLOGIC MALIGNANCIES: SPOTLIGHT ON MULTIPLE MYELOMA

EHA Library, Benedikt Pelzer, 4208499

REAL-WORLD (RW) ELRANATAMAB DOSING PATTERNS AND TIMES TO NEXT TREATMENT (TTNT) AMONG UNITED STATES (US) PATIENTS WITH MULTIPLE MYELOMA (MM): RESULTS FROM THE ALTITUDE-1 & 2 STUDIES

EHA Library, Meera Mohan, 4208500

REAL-WORLD OUTCOMES OF MULTIPLE MYELOMA IN PATIENTS ≥80 YEARS: A BICENTRIC ITALIAN RETROSPECTIVE STUDY AND THE IMPACT OF NOVEL THERAPIES.

EHA Library, Luca Deiana, 4208501

STAGE ALONE IS NOT ENOUGH: INTEGRATING CLONAL BURDEN AND TREATMENT INTENSITY REDEFINES SURVIVAL IN SYSTEMIC AL AMYLOIDOSIS

EHA Library, Güldane Cengiz Seval, 4208502

SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE AND PRIOR RITUXIMAB EXPOSURE: A POST-HOC ANALYSIS OF THE PHASE 3 CADENZA STUDY

EHA Library, Marc Michel, 4208503

MULTI-OMIC CHARACTERIZATION OF INTERFERON-Α DIFFERENTIAL EFFECT ON JAK2V617F MPN AND WILD-TYPE STEM CELLS

EHA Library, Duanya LIU, 4208504

EXPRESSION OF JAK2V617F IN ERYTHROBLASTIC ISLAND MACROPHAGES CONTRIBUTES TO THE PATHOGENESIS OF POLYCYTHEMIA VERA

EHA Library, xiuli An, 4208505

EVOLUTIONARY TRAJECTORY ANALYSIS REVEALS EARLY DETECTION OF LATENT HEMATOPOIETIC STEM CELLS FATED FOR AML IN MYELOFIBROSIS PATIENTS

EHA Library, Jenny Ho, 4208506

DISCOVERY OF A FIRST-IN-CLASS ALLELE-SELECTIVE XNAZYME THAT KNOCKS DOWN MUTANT JAK2 V617F MRNA IN A MOUSE MODEL OF POLYCYTHEMIA VERA

EHA Library, Joel Kaye, 4208507

METABOLIC REWIRING BY ONCOGENIC JAK2V617F CREATES A GLUCOSE TRANSPORT VULNERABILITY IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Julian Baumeister, 4208508

STAT5B INDUCES SEX-SPECIFIC PHENOTYPES IN JAK2 V617F-POSITIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Heidi A. Neubauer, 4208509

DRP1-DEPENDENT MITOCHONDRIAL REPROGRAMMING DRIVES TGF-Β1–INDUCED STROMAL ACTIVATION IN MYELOFIBROSIS

EHA Library, Rose Guignard, 4208510

RUXOLITINIB COMBINED WITH HOMOHARRINGTONINE SYNERGISTICALLY TARGETS CDK2 IN RUXOLITINIB-RESISTANT MYELOFIBROSIS AND SECONDARY ACUTE MYELOID LEUKEMIA

EHA Library, Jian Huang, 4208511

AI-QUANTIFIED BONE MARROW FIBROSIS AND MEGAKARYOCYTE FEATURES CORRELATE WITH DRIVER VAF AND OUTCOMES IN THE MOST MPN STUDY

EHA Library, Len Brandes, 4208512

COMBINED TARGETING OF KDM4 HISTONE DEMETHYLASES REDUCES JAK2V617F-DRIVEN MYELOPROLIFERATION

EHA Library, Hans Staehle, 4208513

SILK-BASED BONE MARROW NICHES ENABLE MECHANISTIC DISSECTION OF STROMAL-REGULATED THROMBOPOIESIS IN HEALTH AND FIBROSIS

EHA Library, Christian Di Buduo, 4208514

THE ORDER OF MYELOID MUTATION ACQUISITION INFLUENCES OUTCOMES IN A LARGE POLYCYTHEMIA VERA COHORT

EHA Library, Paola Guglielmelli, 4208515

JAK2 E837K. FIRST CHARACTERIZATION OF A NOVEL JH2-JH1 INTERDOMAIN LINKER MUTATION DRIVING STAT ACTIVATION AND METABOLIC REPROGRAMMING IN POST-POLYCYTHEMIA VERA MYELOFIBROSIS

EHA Library, Gloria Pasqualini, 4208516

DECIPHERING HEMATOPOIETIC STRESS RESPONSES IN JAK2V617F MYELOPROLIFERATIVE NEOPLASMS: A COMBINED IN VIVO AND MATHEMATICAL MODELING APPROACH

EHA Library, Duanya LIU, 4208517

CRISPR-BASED MODELING OF VARIANTS OF UNCERTAIN SIGNIFICANCE IN MYELOPROLIFERATIVE NEOPLASMS REVEALS REDUCED CLONOGENICITY AND MYELOID-SKEWED DIFFERENTIATION

EHA Library, Antonia-Zoe Kouroutzidou, 4208518

MACHINE LEARNING-DERIVED CIRCULATING INFLAMMATORY PROTEIN SIGNATURE FOR RISK STRATIFICATION IN SYSTEMIC MASTOCYTOSIS

EHA Library, Jennifer Marvin-Peek, 4208519

MECHANISTIC CHARACTERIZATION OF PRURITUS IN MYELOPROLIFERATIVE NEOPLASMS IDENTIFIES C-FIBER SENSORY DYSFUNCTION

EHA Library, Madeline Caduc, 4208520

IDENTIFICATION OF BIOMARKERS TO PREDICT DISEASE PROGRESSION VIA MOLECULAR ANALYSIS OF PATIENTS (PTS) WITH LOW-RISK MYELOFIBROSIS (MF) ENROLLED IN THE MOST STUDY

EHA Library, Naveen Pemmaraju, 4208521

A NOVEL GERMLINE JAK2 MUTATION JAK2G127D COOPERATION WITH JAK2V617F TO ACCELERATE MYELOFIBROSIS PROGRESSION IN MPNS

EHA Library, Yanjie Lan, 4208522

PHYLOGENY, ORDER OF MUTATIONS, AND CELLULAR ORIGIN OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Tetsuichi Yoshizato, 4208523

BEYOND JAK INHIBITION: WT1 AS A BIOMARKER AND THERAPEUTIC TARGET IN HIGH-RISK PRIMARY MYELOFIBROSIS

EHA Library, Jian Huang, 4208524

THE PROGENITOR CELLS AND THE MEGAKARYOCYTES FROM THE BONE MARROW OF THE GATA1LOW MOUSE MODEL OF MYELOFIBROSIS ACQUIRE A STRONG RIBOSOMAL SIGNATURE WITH DISEASE PROGRESSION

EHA Library, Allison Cote, 4208525

TGF-BETA SIGNALING IS DEREGULATED BY TYPE I CALRETICULIN MUTATIONS IN MYELOPROLIFERATIVE NEOPLASM

EHA Library, Aditi Singh, 4208526

FUNCTIONAL ANALYSIS OF A NOVEL GERMLINE JAK2 VARIANT ASSOCIATED WITH THROMBOCYTOSIS

EHA Library, Kateřina Kuželová, 4208527

HETEROGENEOUS CYTOKINE EXPRESSION IN CHRONIC MYELOMONOCYTIC LEUKEMIA: ADVANCES IN DEMETHYLATION THERAPY

EHA Library, Yan Wang, 4208528

PROTEOMIC PROFILING FOR NOVEL BIOMARKERS OF THE PROGRESSION FROM ESSENTIAL THROMBOCYTHEMIA  TO POST-ET MYELOFIBROSIS: A RETROSPECTIVE COHORT STUDY

EHA Library, mingyu Jin, 4208529

THE GENOMIC LANDSCAPE OF MYELOPROLIFERATIVE NEOPLASMS (MPNS) BY DISEASE SUBTYPE: BEYOND JAK2 V617F, CALR, AND MPL

EHA Library, Abhay Singh, 4208530

THE TUMOR-ASSOCIATED FIBROBLAST BIOMARKER PRO-C6 IS ELEVATED IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Caroline Norup Bistrup, 4208531

PLASMA METABOLOMIC LANDSCAPE REVEALS A PROTHROMBOTIC MICROENVIRONMENT AND PREDICTIVE BIOMARKERS IN ESSENTIAL THROMBOCYTHEMIA

EHA Library, mingyu Jin, 4208532

COEXISTENCE OF SF3B1 AND DRIVER MUTATIONS IN MYELOID NEOPLASMS: A CONTINUOUS CLINICAL-MOLECULAR SPECTRUM

EHA Library, Jose Antonio Farah Gamarra, 4208533

MUTANT CALRETICULIN–SPECIFIC MONOCLONAL ANTIBODY, INCA033989, IS WELL TOLERATED AND ACHIEVES RAPID AND SUSTAINED HEMATOLOGIC AND MOLECULAR RESPONSES IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA (ET)

EHA Library, John Mascarenhas, 4208534

FEDRATINIB + NIVOLUMAB COMBINATION IMPROVES OUTCOMES IN MYELOFIBROSIS PATIENTS RESISTANT OR SUBOPTIMALLY RESPONDING TO JAK-INHIBITOR THERAPY – RESULTS FROM THE FRACTION TRIAL (IKF051)

EHA Library, Susanne Isfort, 4208535

INVESTIGATIONAL PIM1 INHIBITOR NUVISERTIB IN COMBINATION WITH MOMELOTINIB SHOWED PROMISING CLINICAL ACTIVITY IN PATIENTS WITH MYELOFIBROSIS AND ANEMIA: DATA FROM AN ONGOING GLOBAL PHASE 1/2 STUDY

EHA Library, James McCloskey, 4208536

ROPEGINTERFERON ALFA-2B DEMONSTRATES MOLECULAR AND HEMATOLOGIC RESPONSES WITH A FAVORABLE SAFETY PROFILE IN ESSENTIAL THROMBOCYTHEMIA

EHA Library, Harinder gILL, 4208537

PELABRESIB MONOTHERAPY IN MYELOFIBROSIS AFTER JANUS KINASE INHIBITOR FAILURE: RESULTS FROM ARM 1 OF THE OPEN-LABEL, PHASE 2 MANIFEST STUDY

EHA Library, Moshe Talpaz, 4208538

SPLICING MUTATIONS PREDICT ANEMIA PROGRESSION AND INFERIOR SURVIVAL IN RUXOLITINIB‑TREATED MYELOFIBROSIS PATIENTS

EHA Library, Chiara Sartor, 4208539

QRISK3 SCORE REINFORCES ITS ROLE IN MPNWITH THE STANDARD 60-YEAR CUT-OFF AND PROVIDES ADDITIVE PROGNOSTIC VALUE TO REVISED-IPSET IN ESSENTIAL THROMBOCYTHEMIA

EHA Library, Andrea Duminuco, 4208540

A NOVEL JAK2 INHIBITOR OB756 FOR POLYCYTHEMIA VERA WITH SPLENOMEGALY: A PHASE IB/II, MULTICENTER STUDY

EHA Library, Jian Huang, 4208541

ANTITHROMBOTIC AND CYTOREDUCTION STRATEGIES IN MYELOPROLIFERATIVE NEOPLASM–ASSOCIATED SPLANCHNIC VEIN THROMBOSIS: A RETROSPECTIVE STUDY FROM THE FRENCH INTERGROUP OF MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Juliette Soret-Dulphy, 4208542

ESTIMATED PULSE WAVE VELOCITY (EPWV) INDEPENDENTLY PREDICTS CARDIOVASCULAR EVENTS IN BCR::ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Alessandro Costa, 4208543

INDIRECT TREATMENT COMPARISON: GECACITINIB VS. PACRITINIB, MOMELOTINIB, AND FEDRATINIB IN FIRST-LINE MYELOFIBROSIS

EHA Library, Yi Zhang, 4208544

MYELOPROLIFERATIVE NEOPLASMS AND MPN-LIKE SYNDROMES WITH NON-CANONICAL  JAK2/MPL VARIANTS. PRELIMINARY RESULTS OF THE ELN MPN-OLIVETTI STUDY

EHA Library, Gonzalo CARRENO, 4208545

OUTCOMES WITH MOMELOTINIB IN PATIENTS WITH INTERMEDIATE-1– VS INTERMEDIATE-2–/HIGH-RISK MYELOFIBROSIS: POST HOC ANALYSES OF THE PHASE 3 SIMPLIFY-1 AND MOMENTUM TRIALS

EHA Library, Prithviraj Bose, 4208546

BEYOND THROMBOSIS: QRISK3 PREDICTS SURVIVAL IN MPN PATIENTS

EHA Library, Danijela Lekovic, 4208547

UPDATE FROM THE PHASE 2 RESTORE TRIAL OF ELRITERCEPT IN PATIENTS WITH MYELOFIBROSIS (MF) RECEIVING RUXOLITINIB

EHA Library, Ciro Rinaldi, 4208548

SUSTAINED CONTROL OF EXCESSIVE ERYTHROPOIESIS BY THE TMPRSS6 ANTISENSE INHIBITOR SAPABLURSEN IN POLYCYTHEMIA VERA: IMPRSSION TRIAL TREATMENT EXTENSION DATA

EHA Library, Pankit Vachhani, 4208549

NOVEL MACHINE LEARNING-BASED MODEL PREDICTS PRESENCE OF ASSOCIATED HEMATOLOGIC NEOPLASMS IN ADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Johannes Lübke, 4208550

LONG-TERM HEMATOLOGIC AND MOLECULAR RESPONSE TO ROPEGINTERFERON ALFA-2B AND CLINICAL VALIDATION OF Q-PCR FOR LOW-LEVEL JAK2 MONITORING IN POLYCYTHEMIA VERA

EHA Library, Sung-Eun Lee, 4208551

CHARACTERIZATION OF SYMPTOMS AFTER IMMEDIATE TRANSITION FROM RUXOLITINIB TO MOMELOTINIB IN PATIENTS WITH MYELOFIBROSIS: POST HOC ANALYSES OF THE PHASE 3 SIMPLIFY-1 AND SIMPLIFY-2 TRIALS

EHA Library, Pankit Vachhani, 4208552

DYNAMIC CYTOPENIA PATTERNS IN MYELOFIBROSIS: A REAL-WORLD ANALYSIS FROM THE ERNEST-3 REGISTRY

EHA Library, Tiziano Barbui, 4208553

INTEGRATED CLINICAL AND MOLECULAR REGISTRY WITH LONGITUDINAL BIOREPOSITORY IN SYSTEMIC MASTOCYTOSIS: A SINGLE-INSTITUTION COHORT

EHA Library, Jennifer Marvin-Peek, 4208554

TP53  MUTATION CHARACTERIZES DIRECT AND ASXL1 AND EZH2 INDIRECT (VIA MYELOFIBROSIS) ET TO AML TRANSITION

EHA Library, Merry Nakhleh, 4208555

SHORESPAN-017: A PHASE 3 EXTENSION STUDY EVALUATING THE SAFETY OF CONTINUED BOMEDEMSTAT IN PARTICIPANTS WITH ESSENTIAL THROMBOCYTHEMIA

EHA Library, Francesca Palandri, 4208556

A PHASE II STUDY OF F182112 IN COMBINATION WITH DARATUMUMAB AND POMALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Tangrong Liu, 4208557

PHENOTYPE-SPECIFIC CHOLESTEROL ELEVATION FOLLOWING RUXOLITINIB IN MPN: ENRICHMENT IN POLYCYTHAEMIA VERA

EHA Library, Elena Torre, 4208558

ROMACICLIB (RVU120), A SELECTIVE CDK8/19 INHIBITOR, AS MONOTHERAPY OR IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: UPDATED RESULTS FROM THE PHASE II POTAMI-61 STUDY

EHA Library, Tomasz Sacha, 4208559

DISEASE MODIFYING EFFECTS OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: IMPACT ON BONE TURNOVER MARKERS (BTMS) AND BONE DISEASE

EHA Library, Johannes Lübke, 4208560

CONSISTENCY OF RESPONSE BY BASELINE PLATELET COUNT IN PACRITINIB-TREATED PATIENTS IN THE REAL WORLD: MY-PAC ANALYSIS

EHA Library, James Rossetti, 4208561

CLINICAL CHARACTERISTICS, MOLECULAR LANDSCAPE AND OUTCOMES OF NON-CMML MDS/MPN OVERLAP SYNDROMES

EHA Library, Yael Morgenstern, 4208562

ASSOCIATION OF CAR, EASIX, AND SII SCORES WITH JAK2 MUTATION STATUS AND THROMBOTIC EVENTS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA

EHA Library, Nergiz Usta, 4208563

ANALYSIS OF VARIANT ALLELE FREQUENCY OF JAK2V617F IN PATIENTS WITH POLYCYTHEMIA VERA TREATED WITH EITHER RUXOLITINIB OR BEST AVAILABLE THERAPY IN THE RANDOMIZED PHASE 2B RUXOBEAT CLINICAL TRIAL

EHA Library, Madeline Caduc, 4208564

COMPARISON OF JAK2-MUTATED ESSENTIAL THROMBOCYTHAEMIA AND POLYCYTHAEMIA VERA IN ADOLESCENTS AND YOUNG ADULTS: CHARACTERISTICS, VASCULAR EVENTS AND LONG-TERM OUTCOME

EHA Library, Maria Georgiou, 4208565

PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH HIGH-RISK CLASSIC HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONT-LINE CHEMOTHERAPY: UPDATED RESULTS FROM KEYNOTE-667

EHA Library, Christine Mauz-Koerholz, 4208566

PROGNOSTIC IMPACT OF METABOLIC TUMOR VOLUME AFTER TWO CYCLES OF ABVD IN EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: A POST-HOC ANALYSIS OF THE GHSG HD16 TRIAL

EHA Library, Justin Ferdinandus, 4208567

COMPARISON OF LONG-TERM EFFICACY BETWEEN THE BRECADD AND N+AVD REGIMENS IN ADVANCED-STAGE HODGKIN LYMPHOMA: A MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON OF THE HD21 AND SWOG S1826 TRIALS

EHA Library, Alexa Molinari, 4208568

FIVE-YEAR CONDITIONAL RELATIVE SURVIVAL UP TO 20 YEARS POST-DIAGNOSIS IN ADULT PATIENTS WITH HODGKIN LYMPHOMA: PERSISTENT EXCESS MORTALITY IN OLDER PATIENTS— A CONTEMPORARY, NATIONWIDE DUTCH STUDY

EHA Library, Fer de Wit, 4208569

PREMENOPAUSAL WOMEN WITH CLASSIC HODGKIN LYMPHOMA HAVE SUPERIOR LYMPHOMA-SPECIFIC SURVIVAL COMPARED TO MEN

EHA Library, Johanna Borg Bruchfeld, 4208570

AUTOLOGOUS STEM CELL TRANSPLANTATION OUTCOMES AFTER ANTI-PD-1 TREATMENT IN THIRD AND SUBSEQUENT LINES FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA

EHA Library, Yulia Protopopova, 4208571

PHARMACOKINETICS, EFFICACY, AND SAFETY OF SUBCUTANEOUS PEMBROLIZUMAB IN RELAPSED OR REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL) OR PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL): A PHASE 2 STUDY

EHA Library, Alejandro Berkovits, 4208572

LATE CARDIOPULMONARY MORBIDITY IN THE PATIENTS WITH HODGKIN LYMPHOMA: A NATIONWIDE REGISTRY STUDY

EHA Library, Noora Hannuksela, 4208573

SURFACE TUMOR EXTENSION (STE) EXTRACTED FROM BASELINE PET/CT PREDICTS LONG-TERM ABVD THERAPY OUTCOME IN ADVANCED-STAGE HODGKIN LYMPHOMA WITH A NEGATIVE INTERIM PET.

EHA Library, Andrea Gallamini, 4208574

LONG-TERM COMPLICATIONS OF THE ABVD PROTOCOL WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA

EHA Library, Nassima Boulaziz, 4208575

COMPARISON OF NIVO-AVD AND STANDARD PET-ADAPTED APPROACH AS FIRST-LINE THERAPY IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA IN REAL-WORLD PRACTICE

EHA Library, Evgenii Kunevich, 4208576

HEART FAILURE SURVIVAL IN PATIENTS WITH PRIOR HODGKIN LYMPHOMA: INCREASED ALL-CAUSE BUT NOT CARDIOVASCULAR MORTALITY

EHA Library, Sissel Johanne Godtfredsen, 4208577

HIGH INCIDENCE AND CLINICAL SIGNIFICANCE OF METABOLIC SYNDROME IN YOUNG HODGKIN LYMPHOMA SURVIVORS: A LARGE MATCHED COHORT STUDY

EHA Library, Dor Shpitzer, 4208578

EVALUATION OF PET-CT METRICS AND PHARMACOKINETICS IN ADULTS RECEIVING TISLELIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: ANCILLARY ANALYSES OF LYSA PHASE 2 TIRHOL STUDY BGB-A317-210

EHA Library, Herve Ghesquieres, 4208579

INCIDENCE AND SURVIVAL OF CLASSIC HODGKIN LYMPHOMA: AN ENGLAND-WIDE COHORT STUDY FROM THE UNCOVER STUDY GROUP, 2014-2022

EHA Library, Sidhant Seth, 4208580